Rodman & Renshaw initiated coverage of BioXcel Therapeutics (BTAI) with a Buy rating and $65 price target The firm sees e blockbuster potential and over 2,900% share upside with BioXCel expanding the use of its approved drug, Igalmi, for at-home use and for Alzheimer’s disease. The convenience of using the drug at home grows the potential by tenfold, with a market potential of $2B in the U.S., the firm tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue